Consensus Annexon, Inc.

Stocks

ANNX

US03589W1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:30:28 2026-07-23 EDT			5-day change	1st Jan Change
5.085 ^USD	-2.77%		-19.54%	+4.18%

06-29	Annexon, Inc.(NasdaqGS:ANNX) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Annexon, Inc.(NasdaqGS:ANNX) added to Russell 2500 Growth Benchmark	CI

Evolution of the Average Target: Annexon, Inc.

Evolution of the Target Price: Annexon, Inc.

Changes in Analyst Recommendations: Annexon, Inc.

4471a0cc968eb.bKFyjysmIruj5Ure-P9AwBU68LU3-uuBfEBb967F6og.Lvsx7B1-e8jPpn-Wma85tVFzt-JWzsbKJA12odrxrtgr1jTib1NA6dGGPQ~09b16dcf510883755a30cfdd350bf525

Analysts' recommendations: Annexon, Inc.

05-12	Goldman Sachs Initiates Annexon at Neutral With $7 Price Target	MT
12-23	Chardan Initiates Annexon at Buy With $16 Price Target	MT
11-10	Annexon Q3 net loss widens to $54.9 mln	RE
24-04-01	JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating	MT
24-03-27	Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating	MT
24-03-01	JPMorgan Upgrades Annexon to Overweight From Neutral, Price Target is $11	MT
23-12-21	BofA Securities Upgrades Annexon to Buy From Neutral	MT
23-12-21	BofA Securities Upgrades Annexon to Buy From Neutral, Adjusts Price Target to $6 From $4	MT
23-05-26	BofA Securities Downgrades Annexon to Neutral From Buy, Adjusts Price Target to $3 From $8	MT
23-05-25	BTIG Lowers Price Target on Annexon to $7 From $15, Maintains Buy Rating	MT
23-05-25	JPMorgan Downgrades Annexon to Neutral From Overweight, Adjusts Price Target to $9 From $19	MT
23-03-14	Cantor Fitzgerald Adjusts Price Target on Annexon to $18 From $22, Maintains Overweight Rating	MT
22-09-16	Jefferies Starts Annexon at Buy With $12 Price Target	MT
22-09-09	BTIG Research Initiates Coverage on Annexon With Buy Rating, Price Target $15	MT
22-08-16	Cantor Fitzgerald Adjusts Annexon's Price Target to $22 From $27, Reiterates Overweight Rating	MT
22-05-10	HC Wainwright Lowers Annexon's Price Target to $30 From $40, Maintains Buy Rating	MT
22-04-08	Needham Adjusts Annexon's Price Target to $24 From $37, Keeps Buy Rating	MT
21-11-30	HC Wainwright Starts Annexon at Buy With $40 Price Target	MT
21-09-23	ANNEXON : Cantor Fitzgerald Starts Annexon Biosciences at Overweight with $40 Price Target	MT
21-01-26	ANNEXON : Needham Starts Annexon at Buy With $37 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ANNEXON, INC.					+159.19%
	WUXI APPTEC CO., LTD.					+19.52%
	ARGENX SE					+15.2%
	INSMED INCORPORATED					+83.97%
	BIONTECH SE					+32.59%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.2%
	GENMAB A/S					+25.17%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+8.92%
	PHARMAESSENTIA CORPORATION					-9.04%
	EXELIXIS, INC.					-7%
	Average					+34.97%
	Weighted average by Cap.					+23.08%